A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
Conclusions: Testing RA patients to learn their ACPA status and increasing use of abatacept among high-titer ACPA patients result in a small increase in the total budget (< 2 cents PMPM).
PMID: 32075453 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Abatacept | Arthritis | Economics | Health Management | Insurance | Learning | Orencia | Rheumatoid Arthritis | Rheumatology | Study | Universities & Medical Training